CRL vs NEUP · rev $2.00B vs rev $15.7M
Charles River Laboratories (CRL) versus Neuphoria Therapeutics Inc (NEUP) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Neuphoria Therapeutics Inc (NEUP) is a biotechnology company listed on NASDAQ.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
Latest reported NEUP revenue for 2025-03-31 was $15.7M. Net income was $8.5M. NEUP currently screens at market cap $23.6M.
CRL currently screens at market cap $7.78B. NEUP currently screens at market cap $23.6M.
Not investment advice. Open the CRL and NEUP stock pages for the full models.
Not investment advice.